CVKD (Cadrenal Therapeutics) Institutional Ownership: 3.05% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVKD Cadrenal Therapeutics Inc CVKD
30 GF Score
Price $1.99
! 2 Warning Signs
View Full Analysis

What is Cadrenal Therapeutics Institutional Ownership?

Cadrenal Therapeutics CVKD -1.97% 30 Institutional Ownership is 3.05% as of Aug. 05, 2026. GuruFocus rates CVKD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cadrenal Therapeutics's institutional ownership is 3.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cadrenal Therapeutics's Insider Ownership is 25.98%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cadrenal Therapeutics's Float Percentage Of Total Shares Outstanding is 85.16%.

Cadrenal Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Cadrenal Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Institutional Ownership Chart

Cadrenal Therapeutics Historical Data

The historical data trend for Cadrenal Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 4.44 4.40 3.52 3.83 3.93 4.19 3.96 3.84 3.61 2.72
CVKD
30GF Score
Cadrenal Therapeutics Inc CVKD
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cadrenal Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.05% mean?
Cadrenal Therapeutics (CVKD) has a Institutional Ownership of 3.05% as of Aug. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cadrenal Therapeutics and its competitors.
Is Cadrenal Therapeutics' Institutional Ownership too high?
Cadrenal Therapeutics' current Institutional Ownership is 3.05%. Overall, Cadrenal Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Institutional Ownership compare to RVPH and IMNN?
Cadrenal Therapeutics' Institutional Ownership of 3.05% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Cadrenal Therapeutics and its competitors. Cadrenal Therapeutics's current Institutional Ownership is 3.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Institutional Ownership of 3.05%. The current Institutional Ownership is 3.05%. Cadrenal Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Institutional Ownership is 3.05% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cadrenal Therapeutics Business Description

Address 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
30GF Score

Get the complete analysis for CVKD

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price